Bae, S I <br/><br/>
Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL.  [electronic resource] 

 -  Oncogene  Jan 2008 
 - 490-8 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1476-5594 
<br/><br/><label>Standard No.: </label>10.1038/sj.onc.1210655  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Apoptosis--drug effects<br/>Azacitidine--analogs & derivatives<br/>Cell Line, Tumor<br/>DNA (Cytosine-5-)-Methyltransferase 1<br/>DNA (Cytosine-5-)-Methyltransferases--antagonists & inhibitors<br/>DNA Methylation--drug effects<br/>Decitabine<br/>Drug Evaluation, Preclinical<br/>Drug Resistance, Neoplasm--drug effects<br/>Drug Synergism<br/>Gene Expression Regulation, Neoplastic--drug effects<br/>Gene Silencing--drug effects<br/>Humans<br/>Interferons--therapeutic use<br/>Melanoma--drug therapy<br/>Receptors, TNF-Related Apoptosis-Inducing Ligand--genetics<br/>TNF-Related Apoptosis-Inducing Ligand--therapeutic use